Fig. 3

Performance of the circRNA biomarker panel to identify early stage GC patients. A ROC curve analysis to identify early stage GC patients from non-disease controls and B Risk score analysis based on risk prediction formulae in early stages (stage I and II), late stages (stage III and IV) GC patients and non-disease control subjects in serum specimens from the training cohort patients. C ROC curve analysis for the identification of early stage GC patients from non-disease controls and D risk score analysis based on risk prediction formulae in early stages (stage I and II), late stages (stage III and IV) GC patients and non-disease controls in serum validation cohort. ROC curves are shown with 95% CIs. Green lines in right panel indicate 95% CIs of sensitivity and specificity for each circRNA; green points, best threshold for sensitivity and specificity